Compare JBS N.V. Class A Common Shares (JBS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Moderna, Inc. — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while Moderna, Inc. trades at $224.94 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 6.2× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays a 10.38% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Moderna, Inc. for 59 Days on average.
| JBS | MRNA | |
|---|---|---|
Market Cap | $13.86B | $86.33B |
Volume | 4,980,049 | 13,361,426 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $226.30 |
52-Week Low | $10.86 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $34.83B | $82.48B |
Dividend Yield | 10.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
